Clinical trials
Vaccination clinical trials
Below are recruiting vaccination clinical trials, each written for real people, not researchers. We’re tracking 575 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07621653Recruiting
Safety check-in after meningococcal vaccine in Korea
This study watches for any side effects or health changes after you receive the MenQuadfi vaccine, which protects against four types of meningococcal bacteria. Your doctor will follow up with you to make sure the vaccine is safe and working well.
BusanAges 1 month–55 years - NCT07626606Recruiting
Gut Health and Rotavirus Vaccine Response in Adults
This study examines how the health of your digestive system affects how well your body responds to an oral rotavirus vaccine (a vaccine given by mouth to protect against rotavirus infection). You'll have two endoscopy procedures—a camera test to look inside your digestive tract—and provide samples to help researchers understand this connection.
Lusaka, Lusaka ProvinceAges 18–50 - NCT07617376RecruitingPhase 4
Flu shot before leaving hospital after heart problems
This study tests whether giving a flu vaccine to patients before they leave the hospital after a heart condition improves their health. The vaccine may help protect your heart and prevent serious flu complications while you recover.
WroclawAges 18 years+ - NCT03888924RecruitingPhase 2
BCG vaccine for people with radiologically isolated syndrome
This trial tests whether a BCG vaccine can help people who have radiologically isolated syndrome (RIS), a condition where MRI scans show signs of possible multiple sclerosis before symptoms develop. The study aims to see if vaccination is safe and can change disease behavior over time.
RomeAges 18 years+ - NCT07592260Recruiting
Nutrition supplements and vaccination uptake in rural Chad and Niger
This study tests whether giving nutrition supplements (SQ-LNS) to healthy young children increases vaccination rates and prevents malnutrition in rural communities in Chad and Niger. Researchers will also track children's health outcomes and interview families about their experiences.
Ngouri, Lac RegionAges 6 months–4.9 years - NCT07585370Recruiting
Long-term Safety and Effectiveness of Shingles Vaccine
This study follows up with people who received an experimental shingles vaccine (a live, weakened form of the virus) in a previous trial from 2020–2021. Researchers want to understand how well the vaccine continues to protect against shingles over time.
Nanjing, JiangsuAges 40 years+ - NCT07583160Enrolling by invitationPhase 1
YS247 Vaccine for Advanced Prostate Cancer
This trial tests a personalized cancer vaccine (YS247) designed to train your immune system to recognize and fight your prostate cancer. It may help slow or stop cancer growth in men whose cancer has spread and stopped responding to standard hormone treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07573462RecruitingPhase 3
Safety study of a new pneumococcal vaccine for infants
This study tests whether a new pneumococcal vaccine (which protects against a serious bacterial infection) is safe in healthy 2-month-old infants. Researchers will watch for side effects and help protect future babies from pneumococcal disease.
Estero, FloridaAges 1 month–3 months - NCT07572864RecruitingPhase 2
Immunotherapy and vaccine before surgery for head and neck cancer
This trial tests a new combination of immunotherapy (a drug that helps your immune system fight cancer) and a mitochondrial vaccine given before surgery for head and neck squamous cell carcinoma. The goal is to help reduce cancer recurrence and improve survival after surgery.
Chengdu, SichuanAges 18 years+ - NCT07565090RecruitingPhase 1
Sudan Virus Vaccine Safety Study for Healthy Adults
This study tests a new experimental vaccine designed to protect against Sudan virus, a rare but serious disease. Researchers will check if the vaccine is safe and helps your immune system fight off the virus.
Washington D.C., District of ColumbiaAges 18–50 - NCT07561723RecruitingPhase 1
IMP3 Vaccine for Advanced Lung Cancer After Treatment Failure
This study tests a new vaccine designed to help your immune system fight advanced lung cancer that has not responded to standard treatments. The vaccine targets a protein called IMP3 found in your cancer cells.
Chengdu, SichuanAges 18 years+ - NCT07555392RecruitingPhase 2/Phase 3
Chikungunya Vaccine Safety and Immune Response Study
This study tests a new vaccine to protect against chikungunya virus, a disease spread by mosquitoes that causes fever and joint pain. The study measures how well your immune system responds to the vaccine and tracks any side effects.
Guwahati, AssamAges 12–65 - NCT07536308RecruitingPhase 1
Nasal COVID-19 booster vaccine safety trial
This trial tests a new nasal spray COVID-19 booster vaccine. It aims to see if the vaccine is safe and produces a strong immune response when given through the nose and inhaled, in people who have already been vaccinated.
Decatur, GeorgiaAges 18–64 - NCT07534007Recruiting
Shingles vaccine response in patients on immune-modifying drugs
This study tests a new shingles vaccine in people with psoriasis or myelofibrosis, some of whom take immune-modifying medications. Researchers want to understand how well the vaccine works and how the immune system responds in these groups.
Pavia, LombardaAges 18–100 - NCT06752057Recruiting
Personalized vaccine plus immunotherapy and radiation for advanced lung cancer
This study tests a combination of a personalized vaccine made from your tumor's unique markers, a type of immunotherapy (PD-1 inhibitor), and radiation. The goal is to see if this mix can work better for advanced lung cancer that has progressed after initial treatment.
Nanchang, JiangxiAges 18–70 - NCT06752044Recruiting
Vaccine, immunotherapy, and radiation for advanced lung cancer
This trial tests a combination of a personalized vaccine (made from your tumor's unique markers), a drug that boosts your immune system (PD-1 inhibitor), and targeted radiation for people with advanced lung cancer that has progressed after initial treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Nanchang, JiangxiAges 18–70 - NCT06751953Recruiting
Neoantigen vaccine plus standard third-line therapy for colorectal cancer
This study tests a vaccine made from your tumor's unique proteins (neoantigens) combined with a standard third-line therapy for colorectal cancer that has worsened after two previous treatments. The goal is to see if this combination helps control the cancer better.
Nanchang, JiangxiAges 18–70 - NCT06751849RecruitingPhase 2
Vaccine, immunotherapy, and radiation for advanced lung cancer
This trial tests a combination of a personalized cancer vaccine, an immunotherapy drug (PD-1 inhibitor), and radiation therapy for people with advanced non-small cell lung cancer that has gotten worse after at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow cancer growth.
Nanchang, JiangxiAges 18–70 - NCT06751901RecruitingPhase 2
Vaccine, immunotherapy, and radiation for advanced lung cancer
This trial tests a combination of a personalized peptide vaccine, an immunotherapy drug (PD-1 inhibitor), and radiation for people with advanced non-small cell lung cancer whose disease has gotten worse after at least two standard treatments. It aims to see if this triple therapy can help control the cancer.
Nanchang, JiangxiAges 18–70 - NCT06751966Recruiting
Peptide vaccine plus standard therapy for advanced colorectal cancer
This trial tests a personalized peptide vaccine (based on your tumor's unique markers) combined with standard third-line therapy for colorectal cancer that has progressed after two prior treatments. The goal is to see if adding the vaccine can help control the cancer better.
Nanchang, JiangxiAges 18–70 - NCT06751940Recruiting
Personalized vaccine plus standard therapy for advanced colorectal cancer
This trial tests a personalized vaccine made from your tumor's unique features, combined with a standard second-line treatment, for colorectal cancer that has worsened after the first treatment. The goal is to see if this combination can help control the cancer better than standard therapy alone.
Nanchang, JiangxiAges 18–70 - NCT06751914Recruiting
Vaccine plus standard therapy for advanced colorectal cancer
This trial tests a personalized vaccine made from your tumor's unique markers, combined with standard second-line treatment, for colorectal cancer that has grown after first treatment. It aims to see if this combination can help control the cancer better.
Nanchang, JiangxiAges 18–70 - NCT07520214Enrolling by invitationEarly Phase 1
Cancer vaccine to prevent glioblastoma recurrence
This early-stage study tests a personalized cancer vaccine designed to prevent glioblastoma (a serious brain tumor) from coming back after surgery and standard treatment. The vaccine aims to train your immune system to recognize and attack any remaining cancer cells.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07502560RecruitingPhase 4
Shingles vaccine to prevent dementia in Finland
This study tests whether the shingles vaccine can reduce the risk of developing dementia in adults 76 and older living in Finland. You would get the vaccine and then researchers will follow your health records for up to several years to see if it protects your brain.
EspooAges 76 years+
Hear when a new Vaccination trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for vaccination?
- Yes. Clin2 currently lists 575 recruiting vaccination studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a vaccination trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a vaccination trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.